Bullet flag-united-kingdom flag-ireland


  • Cystic Fibrosis

Transformational Medicines in Cystic Fibrosis – Learnings from HIV

The introduction of modulator therapies has changed the way people with cystic fibrosis (pwCF) engage with their CF team; many people who were previously very unwell now report improvement in their health and quality of life.

Prior to the introduction of these drugs, the focus of CF care was on managing symptoms and complications associated with the disease, however, CFTR modulator responsive patients now present with a considerably different clinical picture. This transformation in the lives of patients has necessitated a paradigm shift in the multidisciplinary team (MDT) approach with the focus moving from looking after patients who would likely die from CF, to helping patients live with CF.1

The introduction of antiretroviral therapy (ART) in the 1990s for HIV/AIDS had a similar transformative impact on the MDT treatment approach. With the widespread availability of effective ART, HIV became a manageable chronic condition rather than a death sentence, and the focus of the MDT shifted from end-of-life care to long-term management of healthier patients.2

In this webinar, our speakers discuss the similarities and differences of their experiences as members of the CF and HIV MDTs during the introduction of these transformational medicines. Professor Margaret Johnson shares learnings from her experience of the management of patients with HIV whose lives have transformed. Dr Julia Nightingale contextualises these learnings to CF and considers the implications for the CF community in the era of CFTR modulators. 


1. Cuevas-Ocaña S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe. 2020 Jun 1;16(2).

2. Suzy Heafield. Making more of medicines in the drive to end new HIV infections. October 2022. Accessed at: https://www.england.nhs.uk/blog/making-more-of-medicines-in-the-drive-to-end-new-hiv-infections/

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

  • Professor Margaret Johnson

    Consultant in Thoracic and General Medicine, Consultant in HIV/AIDS Medicine and Professor of Medicine

    Read biography
  • Dr Julia Nightingale

    Consultant Respiratory Physician

    Read biography